Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alda Pharmaceuticals has received Patent Number 2007237333 from the Australian Patent Office. The new patent is a divisional of Australian Patent Number 2002322916 that was issued on January 10, 2008 and provides further protection for Alda's T36 formulation until August 20, 2022.
Subscribe to our email newsletter
Alda said that the divisional patent includes claims to additional aspects of the T36 formulation, including the use of T36 as a component of a personal lubricant, in a method of preventing or reducing the transmission of sexually transmitted diseases including Herpes, Chlamydia and HIV and as a sanitizer or cleanser in the form of creams, ointments and wipes. The divisional patent also includes claims to methods of producing T36.
Terrance Owen, president and CEO of Alda, said: “This new Australian patent is another important asset in our intellectual property portfolio because it provides additional protection for T36. It also ties in well with our strategy of registering T36 for therapeutic applications and complements the more recent PCT application which covers a number of additional therapeutic applications.”